| Next 10 |
Ad
PSTV Articles PLUS THERAPEUTICS Inc.
home / stock / pstv / pstv articles
Articles | PLUS THERAPEUTICS Inc. (NASDAQ:PSTV)
-
AUSTIN, Texas, July 02, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), a clinical-stage pharmaceuti...
-
Greg Fuller, M.D., Ph.D., former Professor of Pathology (Neuro-Pathology) & Neuro-Radiology at The University of Texas MD Anderson Cancer Cent...
-
AUSTIN, Texas, May 17, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company...
-
Company acquired assets for the synergistic leptomeningeal metastases (LM) diagnostic platform, "CNSide™" and discussed potential partnerin...
-
AUSTIN, Texas, May 06, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company...
-
Plus Therapeutics Inc (NASDAQ:PSTV) has been selected for $3 million in funding recommendation by the Department of Defense (DoD) office of th...
-
Plus now has $23 million in active awards support for the Company's targeted radiotherapeutic pipeline Funding for pediatric brain cancer tre...
-
AUSTIN, Texas, March 27, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical compa...
-
Plus Receives $3.3M in grant revenue in Q4 2023 Forecasts additional $6.9M of grant revenue for 2024 Enters into debt restructuring deal with Per...
Stock Information
Get PSTV Alerts
News, Short Squeeze, Breakout and More Instantly...
PLUS THERAPEUTICS Inc. Company Name:
PSTV Stock Symbol:
NASDAQ Market:
PLUS THERAPEUTICS Inc. Website:
Ad
-
Rhenium ( 186 Re) Obisbemeda delivered by convection enhanced delivery (CED) continues to show safety, response, and potential efficacy Mean Phase 2 absorbed dose was 300 Gy and 89% of patients exceeded the minimal dose threshold of 100 Gy ReSPECT-GBM Phase 1/2 trial...
-
2024-09-27 20:45:00 ET Recently, I hit a portfolio milestone: $3,800 in annual dividend and interest income. I hit this passive income level when I did my research for an article about my plan to hit $5,000 a year in passive income in 2025. As part of my research, I looked up my project...
-
AUSTIN, Texas, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system can...
Important Investor News Alert (NASDAQ: ZENA)
-
TORONTO, Ontario, Oct. 04, 2024 (GLOBE NEWSWIRE) -- ZenaTech, Inc. (Nasdaq: ZENA) ("ZenaTech"), a technology company specializing in AI (Artificial Intelligence) drone solutions and enterprise SaaS (Software-as-a-Service) solutions, today announced new management team appointments. Craig Passley ...